Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 16, 2011 16:00 ET | Source: Zogenix

Zogenix Reports First Quarter 2011 Financial Results

Confirms 2011 Financial Guidance Conference Call and Web cast Today, May 16th, at 4:30 p.m. ET SUMAVEL® DosePro® U.S. Highlights First quarter 2011 U.S. net product revenue of...
May 11, 2011 07:30 ET | Source: Zogenix

Zogenix to Highlight DosePro(R) Needle-Free Delivery System at 2011 AAPS National Biotechnology Conference

SAN DIEGO, Calif., May 11, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that it will present three posters highlighting its proprietary DosePro® Needle-free Delivery...
May 04, 2011 16:53 ET | Source: Zogenix

Zogenix to Hold Conference Call to Discuss First Quarter 2011 Financial Results

SAN DIEGO, May 4, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced it will release financial results for the first quarter ended March 31, 2011 after market close on Monday, May...
April 13, 2011 07:30 ET | Source: Zogenix

Zogenix Demonstrates Increased Overall Patient Satisfaction With SUMAVEL(R) DosePro(R) Over Multiple Migraine Attacks

SAN DIEGO, April 13, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today reported clinical data from its Phase 4 open-label, multicenter study of SUMAVEL® DosePro ® (sumatriptan...
April 12, 2011 07:30 ET | Source: Zogenix

Zogenix Announces SUMAVEL(R) DosePro(R) Named Patient Program

SAN DIEGO, April 12, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced the establishment of a Named Patient Program for SUMAVEL® DosePro® (sumatriptan injection)...
March 16, 2011 07:30 ET | Source: Zogenix

Zogenix Announces Extension of SUMAVEL(R) DosePro(TM) U.S. Patent Protection by Eight Years

SAN DIEGO, March 16, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
March 03, 2011 16:18 ET | Source: Zogenix

Zogenix Reports Fourth Quarter and Full Year 2010 Financial Results

Provides 2011 Top-line Guidance Conference Call and Webcast Today, March 3rd, at 4:30 p.m. EST SUMAVEL® DosePro™ 2010 Adoption Highlights Fourth quarter 2010 net product revenue...
March 01, 2011 07:30 ET | Source: Zogenix

Zogenix to Present SUMAVEL(R) DosePro(TM) Phase 4 Results at American Academy of Neurology

SAN DIEGO, March 1, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that data from a Phase 4 clinical study of SUMAVEL® DosePro™ (sumatriptan injection) Needle-free...
February 16, 2011 16:30 ET | Source: Zogenix

Zogenix to Hold Conference Call to Discuss Fourth Quarter and Full Year 2010 Financial Results

SAN DIEGO, Feb. 16, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced it will release financial results for the fourth quarter and full year ended December 31, 2010 after market...
February 10, 2011 07:30 ET | Source: Zogenix

Zogenix Announces Completion of Enrollment in ZX002 Phase 3 Efficacy Study

SAN DIEGO, Feb. 10, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today the completion of enrollment in its pivotal Phase 3 efficacy study (Study 801) of ZX002. ZX002 is a novel,...